{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:40:49Z","timestamp":1794663649185,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver fibrosis is a significant complication of chronic liver diseases. While Pirfenidone (PFD) and Liraglutide (LIR) have shown promise individually in treating fibrosis, their combined effect on autophagy and NLRP3 inflammasome pathways remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This study investigated the protective effects of combined LIR and PFD therapy on autophagy and NLRP3 inflammasome, fifty male Wistar rats were divided into five groups: Sham, BDL, BDL\u2009+\u2009PFD (200\u00a0mg\/kg), BDL\u2009+\u2009LIR (200\u00a0\u00b5g\/kg), and BDL\u2009+\u2009PFD\u2009+\u2009LIR combination. Following 20 days of treatment, liver tissues were analyzed for histological and immunohistochemical (IHC) changes, biochemical parameters, and molecular markers of fibrosis, autophagy, and inflammasome activation. The combination therapy significantly reduced serum liver injury markers (ALT, AST, ALP), decreased ECM deposition, and improved histological parameters compared to monotherapy. Combined treatment effectively suppressed inflammatory markers (NF-\u03baB, TNF-\u03b1) while increasing anti-inflammatory IL-10. Furthermore, the combination therapy modulated autophagy markers (Beclin 1), cathepsin B, and reduced NLRP3 inflammasome activation (NLRP3, Caspase 1, IL-1\u03b2, IL-18) more effectively than either drug alone. IHC staining of Ki-67 and HepPar-1 showed that combination therapy enhanced expression of proliferative and differentiation markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PFD and LIR combination therapy demonstrates superior therapeutic efficacy in treating BDL-induced LF through enhanced liver regeneration through enhanced expression of proliferative and differentiation markers and modulation of autophagy and NLRP3 inflammasome pathways, indicating that the combination of PFD and LIR represents a promising therapeutic strategy for LF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04545-z","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:46:33Z","timestamp":1766061993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Protective anti-fibrotic effect of liraglutide and Pirfenidone combination therapy on liver fibrosis in rats: effects on autophagy and NLRP3 inflammasome"],"prefix":"10.1186","volume":"26","author":[{"given":"Zeynab","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Karima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Nourbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas Sahebghadam","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"4545_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151\u201366. https:\/\/doi.org\/10.1038\/s41575-020-00372-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4545_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/apt.15773","volume":"52","author":"IF Villesen","year":"2020","unstructured":"Villesen IF, et al. The signalling and functional role of the extracellular matrix in the development of liver fibrosis. Aliment Pharmacol Ther. 2020;52(1):85\u201397. https:\/\/doi.org\/10.1111\/apt.15773.","journal-title":"Aliment Pharmacol Ther"},{"key":"4545_CR3","doi-asserted-by":"publisher","unstructured":"N AL et al. Protective role of remogliflozin against experimental liver fibrosis by activating AMPK\/SIRT1\/Nrf2 and suppressing NF-\u03baB pathways. Front Pharmacol. 2025;16:1586231. https:\/\/doi.org\/10.3389\/fphar.2025.1586231.","DOI":"10.3389\/fphar.2025.1586231"},{"issue":"11","key":"4545_CR4","doi-asserted-by":"publisher","first-page":"16131","DOI":"10.1007\/s00210-025-04098-8","volume":"398","author":"HM Fayed","year":"2025","unstructured":"Fayed HM, et al. Therapeutic efficacy of Canagliflozin against Epatocarcinogenesis induced by CDD\/DEN\/TAA in a rat model: regulation of AMPK\/HIF-1\u03b1\/YAP-1\/TAZ signaling pathways. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(11):16131\u201348. https:\/\/doi.org\/10.1007\/s00210-025-04098-8.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"4545_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/08923973.2025.2496661","volume":"47","author":"NH Hassan","year":"2025","unstructured":"Hassan NH, et al. Dapagliflozin alleviates thioacetamide induced-liver fibrosis in rats via controlling the Nrf2\/HO-1 and TLR4\/TGF-\u03b21\/PI3K signaling pathways. Immunopharmacol Immunotoxicol. 2025;47(3):392\u2013405. https:\/\/doi.org\/10.1080\/08923973.2025.2496661.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"4545_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bulcan.2020.11.004","volume":"108","author":"W Cao","year":"2021","unstructured":"Cao W, et al. An overview of autophagy: Mechanism, regulation and research progress. Bull Cancer. 2021;108(3):304\u201322. https:\/\/doi.org\/10.1016\/j.bulcan.2020.11.004.","journal-title":"Bull Cancer"},{"issue":"8","key":"4545_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","volume":"24","author":"J Debnath","year":"2023","unstructured":"Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24(8):560\u201375. https:\/\/doi.org\/10.1038\/s41580-023-00585-z.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"4545_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.livres.2023.02.002","volume":"7","author":"Y Wu","year":"2023","unstructured":"Wu Y, et al. Molecular mechanisms of autophagy and implications in liver diseases. Liver Res. 2023;7(1):56\u201370. https:\/\/doi.org\/10.1016\/j.livres.2023.02.002.","journal-title":"Liver Res"},{"key":"4545_CR9","doi-asserted-by":"publisher","first-page":"100973","DOI":"10.1016\/j.mam.2021.100973","volume":"Dec","author":"H Qian","year":"2021","unstructured":"Qian H, et al. Autophagy in liver diseases: A review. Mol Aspects Med. 2021;Dec:82:100973. https:\/\/doi.org\/10.1016\/j.mam.2021.100973.","journal-title":"Mol Aspects Med"},{"issue":"6","key":"4545_CR10","first-page":"5747","volume":"13","author":"M Sun","year":"2021","unstructured":"Sun M, Tan L, Hu M. The role of autophagy in hepatic fibrosis. Am J Transl Res. 2021;13(6):5747\u201357. eCollection 2021.","journal-title":"Am J Transl Res"},{"key":"4545_CR11","doi-asserted-by":"publisher","unstructured":"Tao Y, et al. The role of autophagy and NLRP3 inflammasome in liver fibrosis. Biomed Res Int. 2020;11:2020:7269150. https:\/\/doi.org\/10.1155\/2020\/7269150.","DOI":"10.1155\/2020\/7269150"},{"key":"4545_CR12","doi-asserted-by":"publisher","unstructured":"Fujita T, Narumiya S. Roles of hepatic stellate cells in liver inflammation: a new perspective. Inflamm Regen 2016:36:1. https:\/\/doi.org\/10.1186\/s41232-016-0005-6","DOI":"10.1186\/s41232-016-0005-6"},{"issue":"10","key":"4545_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20(10):633\u201346. https:\/\/doi.org\/10.1038\/s41575-023-00807-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4545_CR14","doi-asserted-by":"publisher","unstructured":"Fayed HM, et al. Therapeutic efficacy of Canagliflozin against hepatocarcinogenesis induced by CDD\/DEN\/TAA in a rat model: regulation of AMPK\/HIF-1\u03b1\/YAP-1\/TAZ signaling pathways. Naunyn Schmiedebergs Arch Pharmacol. 2025;29. https:\/\/doi.org\/10.1007\/s00210-025-04098-8.","DOI":"10.1007\/s00210-025-04098-8"},{"issue":"12","key":"4545_CR15","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.3390\/ijms21124223","volume":"21","author":"R Fusco","year":"2020","unstructured":"Fusco R, et al. Focus on the role of NLRP3 inflammasome in diseases. Int J Mol Sci. 2020;21(12):4223. https:\/\/doi.org\/10.3390\/ijms21124223.","journal-title":"Int J Mol Sci"},{"key":"4545_CR16","doi-asserted-by":"publisher","first-page":"100889","DOI":"10.1016\/j.mam.2020.100889","volume":"Dec","author":"L Wang","year":"2020","unstructured":"Wang L, Hauenstein AV. The NLRP3 inflammasome: mechanism of action, role in disease and therapies. Mol Aspects Med. 2020;Dec:76:100889. https:\/\/doi.org\/10.1016\/j.mam.2020.100889.","journal-title":"Mol Aspects Med"},{"key":"4545_CR17","doi-asserted-by":"publisher","unstructured":"Wang Z et al. NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev 2020:2020:4063562. https:\/\/doi.org\/10.1155\/2020\/4063562","DOI":"10.1155\/2020\/4063562"},{"issue":"5","key":"4545_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","volume":"18","author":"S Paik","year":"2021","unstructured":"Paik S, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021;18(5):1141\u201360. https:\/\/doi.org\/10.1038\/s41423-021-00670-3.","journal-title":"Cell Mol Immunol"},{"issue":"5876","key":"4545_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1126\/science.1156995","volume":"320","author":"C Dostert","year":"2008","unstructured":"Dostert C, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320(5876):674\u20137. https:\/\/doi.org\/10.1126\/science.1156995.","journal-title":"Science"},{"issue":"12","key":"4545_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He Y, Hara H, N\u00fa\u00f1ez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012\u201321. https:\/\/doi.org\/10.1016\/j.tibs.2016.09.002.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"4545_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","volume":"26","author":"Q Lv","year":"2020","unstructured":"Lv Q, et al. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3\u03b2\/\u03b2-catenin and TGF-\u03b21\/Smad2\/3 signaling pathways. Mol Med. 2020;26(1):49. https:\/\/doi.org\/10.1186\/s10020-020-00173-3.","journal-title":"Mol Med"},{"key":"4545_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.fct.2017.12.034","volume":"Feb:112","author":"F Pourgholamhossein","year":"2018","unstructured":"Pourgholamhossein F, et al. Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression. Food Chem Toxicol. 2018;Feb:112:39\u201346. https:\/\/doi.org\/10.1016\/j.fct.2017.12.034.","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"4545_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","volume":"15","author":"K Hostettler","year":"2014","unstructured":"Hostettler K, et al. Anti-fibrotic effects of Pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15(1):157. https:\/\/doi.org\/10.1186\/s12931-014-0157-3.","journal-title":"Respir Res"},{"issue":"1","key":"4545_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.14218\/JCTH.2019.00056","volume":"8","author":"CA Philips","year":"2020","unstructured":"Philips CA, et al. Repurposing Pirfenidone for nonalcoholic steatohepatitis-related cirrhosis: A case series. J Clin Transl Hepatol. 2020;8(1):100\u20135. https:\/\/doi.org\/10.14218\/JCTH.2019.00056.","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"4545_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1440-1681.2001.03481.x","volume":"28","author":"S Tada","year":"2001","unstructured":"Tada S, et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp P Normalization Acol Physiol. 2001;28(7):522\u20137. https:\/\/doi.org\/10.1046\/j.1440-1681.2001.03481.x.","journal-title":"Clin Exp P Normalization Acol Physiol"},{"issue":"5","key":"4545_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/s0168-8278(02)00245-3","volume":"37","author":"A Di Sario","year":"2002","unstructured":"Di Sario A, et al. Effect of Pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002;37(5):584\u201391. https:\/\/doi.org\/10.1016\/s0168-8278(02)00245-3.","journal-title":"J Hepatol"},{"issue":"1\u20133","key":"4545_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","volume":"595","author":"A Salazar-Montes","year":"2008","unstructured":"Salazar-Montes A, et al. Potent antioxidant role of Pirfenidone in experimental cirrhosis. Eur J Pharmacol. 2008;595(1\u20133):69\u201377. https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.110.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"4545_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1440-1681.2009.05194.x","volume":"36","author":"XY Zhao","year":"2009","unstructured":"Zhao XY, et al. Pirfenidone inhibits carbon tetrachloride-and albumin complex\u2010induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol. 2009;36(10):963\u20138. https:\/\/doi.org\/10.1111\/j.1440-1681.2009.05194.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4545_CR29","doi-asserted-by":"publisher","unstructured":"Komiya C et al. Antifibrotic effect of Pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci Rep. 2017;7:44754. https:\/\/doi.org\/10.1038\/srep44754","DOI":"10.1038\/srep44754"},{"key":"4545_CR30","doi-asserted-by":"publisher","unstructured":"Dong Q, et al. Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. Front Med (Lausanne). 2023;20:10:1120621. https:\/\/doi.org\/10.3389\/fmed.2023.1120621.","DOI":"10.3389\/fmed.2023.1120621"},{"issue":"11","key":"4545_CR31","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3390\/jcm11112998","volume":"11","author":"JJ Barboza","year":"2022","unstructured":"Barboza JJ, et al. Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2022;11(11):2998. https:\/\/doi.org\/10.3390\/jcm11112998.","journal-title":"J Clin Med"},{"key":"4545_CR32","doi-asserted-by":"publisher","unstructured":"Alruwaili H, Dehestani B, Roux CW. Clinical impact of liraglutide as a treatment of obesity. Clinical pharmacology. Clin Pharmacol. 2021;13:53\u201360. https:\/\/doi.org\/10.2147\/CPAA.S276085","DOI":"10.2147\/CPAA.S276085"},{"issue":"1","key":"4545_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4274\/balkanmedj.galenos.2023.2023-8-44","volume":"41","author":"L Shi","year":"2024","unstructured":"Shi L, et al. The key role of liraglutide in preventing autophagy of vascular smooth muscle cells in high glucose conditions. Balkan Med J. 2024;41(1):54\u201363. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2023.2023-8-44.","journal-title":"Balkan Med J"},{"key":"4545_CR34","doi-asserted-by":"publisher","unstructured":"Liao Z et al. Liraglutide improves nonalcoholic fatty liver disease in diabetic mice by activating autophagy through AMPK\/mTOR signaling pathway. Diabetes Metab Syndr Obes. 2024;17:575\u201384. https:\/\/doi.org\/10.2147\/DMSO.S447182","DOI":"10.2147\/DMSO.S447182"},{"issue":"6","key":"4545_CR35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0168-8278(02)00272-6","volume":"37","author":"L Garc\u00eda","year":"2002","unstructured":"Garc\u00eda L, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol. 2002;37(6):797\u2013805. https:\/\/doi.org\/10.1016\/s0168-8278(02)00272-6.","journal-title":"J Hepatol"},{"key":"4545_CR36","doi-asserted-by":"publisher","unstructured":"Knudsen LB. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl. 2010;(167):4\u201311. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02499.x","DOI":"10.1111\/j.1742-1241.2010.02499.x"},{"key":"4545_CR37","doi-asserted-by":"publisher","unstructured":"Zhou R et al. Liraglutide alleviates hepatic steatosis and liver injury in T2MD rats via a GLP-1R dependent AMPK pathway. Front Pharmacol. 2021:11600175. https:\/\/doi.org\/10.3389\/fphar.2020.600175","DOI":"10.3389\/fphar.2020.600175"},{"key":"4545_CR38","doi-asserted-by":"publisher","unstructured":"Van Campenhout S, Van Vlierberghe H, Devisscher L. Common bile duct ligation as model for secondary biliary cirrhosis. Methods Mol Biol. 2019:1981:237\u201347. https:\/\/doi.org\/10.1007\/978-1-4939-9420-5_15","DOI":"10.1007\/978-1-4939-9420-5_15"},{"issue":"2","key":"4545_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/dna.2024.0194","volume":"44","author":"Z Yousefi","year":"2025","unstructured":"Yousefi Z, Nourbakhsh M, Sahebghadam Lotfi A. Pirfenidone downregulates eIF6, P311, and TGF-\u03b2 expression and improves liver fibrosis induced by bile duct ligation in Wistar rats: evidence for liver regeneration. DNA Cell Biol. 2025;44(2):109\u201324. https:\/\/doi.org\/10.1089\/dna.2024.0194.","journal-title":"DNA Cell Biol"},{"issue":"5","key":"4545_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.6050","volume":"95","author":"P Georgiev","year":"2008","unstructured":"Georgiev P, et al. Characterization of time-related changes after experimental bile duct ligation. Br J Surg. 2008;95(5):646\u201356. https:\/\/doi.org\/10.1002\/bjs.6050.","journal-title":"Br J Surg"},{"key":"4545_CR41","doi-asserted-by":"publisher","unstructured":"Tag CG et al. Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J Vis Exp. 2015;(96):52438. https:\/\/doi.org\/10.3791\/52438","DOI":"10.3791\/52438"},{"key":"4545_CR42","doi-asserted-by":"publisher","unstructured":"Tan Z, et al. Liver fibrosis: therapeutic targets and advances in drug therapy. Front Cell Dev Biol. 2021;21:9:730176. https:\/\/doi.org\/10.3389\/fcell.2021.730176.","DOI":"10.3389\/fcell.2021.730176"},{"key":"4545_CR43","doi-asserted-by":"publisher","unstructured":"Shan L et al. New drugs for hepatic fibrosis. Front Pharmacol 2022;13874408. https:\/\/doi.org\/10.3389\/fphar.2022.874408","DOI":"10.3389\/fphar.2022.874408"},{"issue":"5","key":"4545_CR44","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, et al. Glucagon-like peptide\u20101 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584\u201392. https:\/\/doi.org\/10.1002\/hep.23569.","journal-title":"Hepatology"},{"issue":"6","key":"4545_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2174\/0118715303180615231011053011","volume":"24","author":"AM Salehi","year":"2024","unstructured":"Salehi AM, et al. Liraglutide and liver injury: rare case report with literature review. Endocr Metab Immune Disord Drug Targets. 2024;24(6):725\u20139. https:\/\/doi.org\/10.2174\/0118715303180615231011053011.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"4545_CR46","doi-asserted-by":"publisher","unstructured":"Antar SA, Saleh MA, Al-Karmalawy AA. Investigating the possible mechanisms of Pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and\/or anti-SARS-CoV-2. Life Sci. 2022:309121048. https:\/\/doi.org\/10.1016\/j.lfs.2022.121048","DOI":"10.1016\/j.lfs.2022.121048"},{"issue":"2","key":"4545_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbrc.2018.09.134","volume":"505","author":"W Zhu","year":"2018","unstructured":"Zhu W, et al. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet. Biochem Biophys Res Commun. 2018;505(2):523\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2018.09.134.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"4545_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/jcm8030339","volume":"8","author":"J Sampedro","year":"2019","unstructured":"Sampedro J, et al. New insights into the mechanisms of action of topical administration of GLP-1 in an experimental model of diabetic retinopathy. J Clin Med. 2019;8(3):339. https:\/\/doi.org\/10.3390\/jcm8030339.","journal-title":"J Clin Med"},{"key":"4545_CR49","doi-asserted-by":"publisher","unstructured":"He Y, et al. The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. Ann Hepatol. 2020;19(1):44\u201352. https:\/\/doi.org\/10.1016\/j.aohep.2019.06.023.","DOI":"10.1016\/j.aohep.2019.06.023"},{"issue":"13","key":"4545_CR50","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1080\/14656566.2020.1774553","volume":"21","author":"J Lambrecht","year":"2020","unstructured":"Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother. 2020;21(13):1637\u201350. https:\/\/doi.org\/10.1080\/14656566.2020.1774553.","journal-title":"Expert Opin Pharmacother"},{"key":"4545_CR51","doi-asserted-by":"publisher","unstructured":"Mac\u00edas-Barrag\u00e1n J, et al. The multifaceted role of Pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;1:3:16. https:\/\/doi.org\/10.1186\/1755-1536-3-16.","DOI":"10.1186\/1755-1536-3-16"},{"key":"4545_CR52","doi-asserted-by":"publisher","unstructured":"Tan Y, et al. Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022;10:13935180. https:\/\/doi.org\/10.3389\/fendo.2022.935180.","DOI":"10.3389\/fendo.2022.935180"},{"issue":"12","key":"4545_CR53","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1136\/gutjnl-2014-308410","volume":"64","author":"L Dubuquoy","year":"2015","unstructured":"Dubuquoy L, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut. 2015;64(12):1949\u201360. https:\/\/doi.org\/10.1136\/gutjnl-2014-308410.","journal-title":"Gut"},{"issue":"2\u20133","key":"4545_CR54","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.foodchem.2012.11.094","volume":"138","author":"M-F Lee","year":"2013","unstructured":"Lee M-F, et al. Pterostilbene inhibits dimethylnitrosamine-induced liver fibrosis in rats. Food Chem. 2013;138(2\u20133):802\u20137. https:\/\/doi.org\/10.1016\/j.foodchem.2012.11.094.","journal-title":"Food Chem"},{"issue":"3","key":"4545_CR55","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0394632015621319","volume":"29","author":"\u0130 Bing\u00fcl","year":"2016","unstructured":"Bing\u00fcl \u0130, et al. Blueberry treatment attenuated cirrhotic and preneoplastic lesions and oxidative stress in the liver of diethylnitrosamine-treated rats. Int J Immunopathol Pharmacol. 2016;29(3):426\u201337. https:\/\/doi.org\/10.1177\/0394632015621319.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4545_CR56","doi-asserted-by":"publisher","unstructured":"Mohamad MI et al. Pterostilbene ameliorates the disrupted Adars expression and improves liver fibrosis in DEN-induced liver injury in Wistar rats: A novel potential effect. Gene 2022:813146124. https:\/\/doi.org\/10.1016\/j.gene.2021.146124","DOI":"10.1016\/j.gene.2021.146124"},{"issue":"9","key":"4545_CR57","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/iub.2625","volume":"74","author":"J Wu","year":"2022","unstructured":"Wu J, et al. Ferulic acid ameliorates acetaminophen-induced acute liver injury by promoting AMPK\u2010mediated protective autophagy. IUBMB Life. 2022;74(9):880\u201395. https:\/\/doi.org\/10.1002\/iub.2625.","journal-title":"IUBMB Life"},{"issue":"27","key":"4545_CR58","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1021\/acs.jafc.0c01901","volume":"68","author":"J Kang","year":"2020","unstructured":"Kang J, et al. Ferulic acid inactivates Shigella flexneri through cell membrane destruction, biofilm retardation, and altered gene expression. J Agric Food Chem. 2020;68(27):7121\u201331. https:\/\/doi.org\/10.1021\/acs.jafc.0c01901.","journal-title":"J Agric Food Chem"},{"issue":"8","key":"4545_CR59","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/liv.13866","volume":"38","author":"X Chao","year":"2018","unstructured":"Chao X, et al. Role and mechanisms of autophagy in acetaminophen-induced liver injury. Liver Int. 2018;38(8):1363\u201374. https:\/\/doi.org\/10.1111\/liv.13866.","journal-title":"Liver Int"},{"key":"4545_CR60","doi-asserted-by":"publisher","unstructured":"Biasizzo M, Kopitar-Jerala N. Interplay between NLRP3 inflammasome and autophagy. Front Immunol. 2020;9:11591803. https:\/\/doi.org\/10.3389\/fimmu.2020.591803.","DOI":"10.3389\/fimmu.2020.591803"},{"issue":"3","key":"4545_CR61","doi-asserted-by":"publisher","first-page":"G377","DOI":"10.1152\/ajpgi.00124.2016","volume":"311","author":"G Lalazar","year":"2016","unstructured":"Lalazar G, et al. Autophagy confers resistance to lipopolysaccharide-induced mouse hepatocyte injury. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G377\u201386. https:\/\/doi.org\/10.1152\/ajpgi.00124.2016.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"11","key":"4545_CR62","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41419-020-03176-4","volume":"11","author":"L Shao","year":"2020","unstructured":"Shao L, et al. IL-22 ameliorates LPS-induced acute liver injury by autophagy activation through ATF4-ATG7 signaling. Cell Death Dis. 2020;11(11):970. https:\/\/doi.org\/10.1038\/s41419-020-03176-4.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4545_CR63","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41467-017-00213-3","volume":"8","author":"J Cosin-Roger","year":"2017","unstructured":"Cosin-Roger J, et al. Hypoxia ameliorates intestinal inflammation through NLRP3\/mTOR downregulation and autophagy activation. Nat Commun. 2017;8(1):98. https:\/\/doi.org\/10.1038\/s41467-017-00213-3.","journal-title":"Nat Commun"},{"key":"4545_CR64","doi-asserted-by":"publisher","unstructured":"Li C, et al. Oridonin alleviates LPS-induced depression by inhibiting NLRP3 inflammasome via activation of autophagy. Front Med (Lausanne). 2022;12:8:813047. https:\/\/doi.org\/10.3389\/fmed.2021.813047.","DOI":"10.3389\/fmed.2021.813047"},{"key":"4545_CR65","doi-asserted-by":"publisher","unstructured":"Peng W et al. Autophagy alleviates mitochondrial DAMP-induced acute lung injury by inhibiting NLRP3 inflammasome. Life Sci. 2021;265:118833. https:\/\/doi.org\/10.1016\/j.lfs.2020.118833","DOI":"10.1016\/j.lfs.2020.118833"},{"issue":"3","key":"4545_CR66","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.bmc.2010.10.028","volume":"19","author":"D Cagli\u010d","year":"2011","unstructured":"Cagli\u010d D, et al. Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation. Bioorg Med Chem. 2011;19(3):1055\u201361. https:\/\/doi.org\/10.1016\/j.bmc.2010.10.028.","journal-title":"Bioorg Med Chem"},{"issue":"33","key":"4545_CR67","doi-asserted-by":"publisher","first-page":"11330","DOI":"10.1523\/JNEUROSCI.0677-12.2012","volume":"32","author":"L Sun","year":"2012","unstructured":"Sun L, et al. Microglial cathepsin B contributes to the initiation of peripheral inflammation-induced chronic pain. J Neurosci. 2012;32(33):11330\u201342. https:\/\/doi.org\/10.1523\/JNEUROSCI.0677-12.2012.","journal-title":"J Neurosci"},{"issue":"10","key":"4545_CR68","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","volume":"11","author":"SL Masters","year":"2010","unstructured":"Masters SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes. Nat Immunol. 2010;11(10):897\u2013904. Epub 2010 Sep 12.","journal-title":"Nat Immunol"},{"issue":"3","key":"4545_CR69","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-018-0378-3","volume":"9","author":"T-T Tang","year":"2018","unstructured":"Tang T-T, et al. Hydroxychloroquine attenuates renal ischemia\/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. Cell Death Dis. 2018;9(3):351. https:\/\/doi.org\/10.1038\/s41419-018-0378-3.","journal-title":"Cell Death Dis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04545-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04545-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04545-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:23:26Z","timestamp":1781623406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04545-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4545"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04545-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Endocrinology and Metabolism Research Institute's Ethical Committee at Tehran University of Medical Sciences gave its approval to the study (IR.TUMS.AEC.1402.137).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}